Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04400383
Other study ID # AB011-ST-01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date June 4, 2020
Est. completion date September 28, 2023

Study information

Verified date May 2024
Source CARsgen Therapeutics Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.


Description:

This study is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors. The study is composed of two stages: stage I is single treatment and stage II is combo treatment.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date September 28, 2023
Est. primary completion date July 8, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Stage 1: Inclusion Criteria: - 1. Aged 18 to 80 years, either sex; - 2. Patients with histologically or cytologic confirmed advanced solid tumors should have failed the standard treatment, or have no standard treatment regimen available, or have no access to standard treatment; - 3. Tumor tissue samples is CLDN18.2 positive; - 4. According to RECIST1.1, there are at least one evaluable tumor lesion during dose escalation period (stage 1), and at least one measurable tumor lesion during dose expansion period (stage 2); - 5. The ECOG score is 0 to 1; - 6. Expected survival > 3 months; - 7. Various organs in good condition; - 8. Fertile eligible patients (male and female) and their partners are willing to use a reliable method of contraception (hormones, barriers or abstinence) during the study and within 90 days after the last study treatment; women of childbearing potential must be tested for serum or urine pregnancy within 7 days before enrollment with negative results; - 9. Patients are informed of this study before the trial and sign written informed consent form. Exclusion Criteria: - 1. Received anti-tumor therapies within 4 weeks prior to first administration of study drug, except: within 6 weeks for nitrosoureas or mitomycin C, within 2 weeks or 5 half-life of drugs (whichever longer) for oral fluorouracils and small molecular targeted drugs, and within 2 weeks for traditional Chinese medicines with indications of anti-tumor; - 2. Received other non-marketed clinical trial drugs within 4 weeks prior to first administration of study drugs; - 3. Received major surgery or had significant trauma within 4 weeks prior to first administration of study drug; - 4. Received systemic corticosteroids or other immunosuppressors within 14 days prior to first administration of study drug; - 5. Patients with AEs from previous treatment that have not recovered to =1 (CTCAE 5.0 ); - 6. Patients have central nervous system (CNS) metastasis or meningeal metastasis, or other evidences which demonstrate the CNS metastasis or meningeal metastasis are not controlled, resulting that patients are not eligible for enrollment at the investigator's discretion; - 7. Patients with any active infection which requires systemic treatment with of anti-infection currently; - 8. Patients with medical history of immune deficiency; - 9. Patients with hepatitis B; - 10.Patients with HCV infection but who with the HCV-RNA lower than the lower limit of detection can be enrolled ; - 11.Patients with interstitial lung disease or Pulmonary function abnormalities which were identified by the investigator as clinically significant; - 12.Patients who received any anti-CLDN18.2 treatment; - 13.Patients with significant medical history of cardiovascular and cerebrovascular diseases; - 14.Patient with high risks of gastrointestinal hemorrhage at the investigator's discretion; - 15.Patients who need long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) ; - 16.Known alcohol use or drug dependence; - 17.Patients with mental disorders or poor compliance; - 18.Pregnant or lactating women; - 19.Past severe allergic reactions or allergies to known components of AB011 injection ; - 20.Persistent recurrent vomiting (defined as =3 vomiting in 24 hours); - 21. Have other uncured malignant tumors in the past 5 years or at the same time, except cervical carcinoma in situ, basal cell carcinoma of the skin and other tumors with very low malignant degree; - 22.Live attenuated vaccine was administered within 4 weeks prior to initial administration of the study drug; - 23.Patients who with other serious systemic diseases or cannot participate in this trial due to other reasons, at the investigator's discretion. Stage 2: Inclusion Criteria: - 1. Aged 18 to 80 years, either sex; - 2. Patients with histologically or cytologic confirmed advanced gastric/oesophagus- gastric junction cancer or pancreatic cancer without systemic therapy (neoadjuvant therapy or postoperative adjuvant therapy, no tumor progression or recurrence within 6 months of last medication) - 3. Tumor tissue samples is CLDN18.2 positive ; - 4. According to RECIST1.1, there are at least one evaluable tumor lesion during dose escalation period (stage 1), and at least one measurable tumor lesion during dose expansion period (stage 2); - 5. The ECOG score is 0 to 1; - 6. Expected survival > 3 months; - 7. Various organs in good condition; - 8. Fertile eligible patients (male and female) and their partners are willing to use a reliable method of contraception (hormones, barriers or abstinence) during the study and within 90 days after the last study treatment; women of childbearing potential must be tested for serum or urine pregnancy within 7 days before enrollment with negative results; - 9. Patients are informed of this study before the trial and sign written informed consent form. Exclusion Criteria: - 1. Received any other unmarketed investigational drug within 4 weeks prior to initial use of the investigational drug; - 2. Patients with gastric adenocarcinoma and gastric cancer/esophagogastric junction adenocarcinoma have allergies, intolerations, contraindications or other unsuitable applications of capecitabine or oxaliplatin regimen (such as complete lack of known dihydropyrimidine dehydrogenase activity, etc.);Subjects with pancreatic cancer have allergies, intolerations, contraindications, or other inappropriate use of gemcitabine, other drugs or any of the components that may be used in the albumin-bound paclitaxel regimen; - 3. If the patient has received local treatment such as radiotherapy for locally advanced unresectable or metastatic gastric/oesophagogastric junction cancer or pancreatic cancer, unless the treatment was completed >28 days before the first administration of the study drug.Patients who received palliative radiotherapy with peripheral bone metastases and recovered from all acute toxicity = 14 days prior to initial administration of the study therapy were eligible for inclusion; - 4. Patients with gastric/oesophagogastric junction carcinoma are known to have grade =2 peripheral sensory neuropathy, unless loss of deep tendon reflex is the only neurological abnormality; - 5. Major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to initial use of the study drug; - 6.Received systemic glucocorticoid (prednisone > 10mg/ day or equivalent dose of the same drug) or other immunosuppressant treatment within 14 days prior to initial use of the study drug; The exceptions are: local, ocular, intraarticular, intranasal, and inhaled glucocorticoids;Short-term use of glucocorticoids for prophylactic treatment (e.g. to prevent contrast allergy); - 7.Patients with AEs from previous treatment that have not recovered to =1(CTCAE 5.0); - 8. Patients have central nervous system (CNS) metastasis or meningeal metastasis, or other evidences which demonstrate the CNS metastasis or meningeal metastasis are not controlled, resulting that patients are not eligible for enrollment at the investigator's discretion; - 9. Patients with any active infection which requires systemic treatment with of anti-infection currently; - 10. Patients with medical history of immune deficiency, Including positive HIV antibodies; - 11. Patients with hepatitis B; - 12.Patients with HCV infection but who with the HCV-RNA lower than the lower limit of detection can be enrolled ; - 13.Patients who have interstitial lung disease or Pulmonary function abnormalities which were identified by the investigator as clinically significant; - 14.Patients received any anti-CLDN18.2 treatment; - 15.Patients with have significant medical history of cardiovascular and cerebrovascular diseases; - 16.Patient with high risks of gastrointestinal hemorrhage at the investigator's discretion; - 17.Patients who need long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) ; - 18.Known alcohol use or drug dependence; - 19.Patients with mental disorders or poor compliance; - 20.Pregnant or lactating women; - 21.Past severe allergic reactions or allergies to known components of AB011 injection; - 22.Persistent recurrent vomiting (defined as =3 vomiting in 24 hours); - 23. Have other uncured malignant tumors in the past 5 years or at the same time, except cervical carcinoma in situ, basal cell carcinoma of the skin and other tumors with very low malignant degree; - 24.Live attenuated vaccine was administered within 4 weeks prior to initial administration of the study drug; - 25.Patients have other serious systemic diseases or cannot participate in this trial due to other reasons, at the investigator's discretion.

Study Design


Intervention

Drug:
AB011 Injection
Stage 1 Single treatment: AB011 Injection with dose escalation of 1mg/kg up to 40mg/kg, as well as dose expansion with recommended dose level from dose escalation. Stage 2 Combo Treatment: AB011 combine XELOX( GC) or Gem/nab-P (PC) Injection with dose escalation of 10mg/kg up to 30mg/kg, as well as dose expansion with recommended dose level from dose escalation.

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing
China Xiangya Hospital Central South University Changsha Hunan
China Sir Run Run Shaw Hospital Hangzhou Zhejiang
China The First Affiliated Hospital, Zhejiang University Hangzhou Zhejiang
China Harbin Medical University Cancer Hospital Harbin Heilongjiang
China Anhui Provincial Hospital Hefei Anhui
China Huaihua Second People's Hospital Huaihua Hunan
China Linyi Cancer Hospital Linyi Shandong
China Shanghai East Hospital Shanghai Shanghai
China Zhongshan Hospital, Zhongshan University Shanghai Shanghai
China Henan Cancer Hospital Zhengzhou Henan
China The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan

Sponsors (2)

Lead Sponsor Collaborator
CARsgen Therapeutics Co., Ltd. Shanghai East Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Stage1:Incidence of adverse events AE of single and multiple dose (according to NCI CTCAE 5.0) An AE or SAE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. From First dose to last patient progression or 6 months, whichever came first
Primary Stage1:Incidence of adverse events SAE of single and multiple dose (according to NCI CTCAE 5.0) An AE or SAE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. From First dose to last patient progression or 6 months, whichever came first
Primary Stage 1: The incidence and case number of DLT (Dose Limiting Toxicity) during observation period DLT is short for Dose Limiting Toxicity. dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment. From first dose up to 28 days
Primary Stage 2:Incidence of adverse events AE of single and multiple dose for AB011 combinate with XELOX or Gem/nab-P (according to NCI CTCAE 5.0) An AE or SAE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. From First dose to last patient progression or 12 months, whichever came first
Primary Stage 2:Incidence of adverse events SAE of single and multiple dose for AB011 combinate with XELOX or Gem/nab-P (according to NCI CTCAE 5.0) An AE or SAE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. From First dose to last patient progression or 12 months, whichever came first
Primary Stage 2: The incidence and case number of DLT (Dose Limiting Toxicity) during observation period DLT is short for Dose Limiting Toxicity. dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment. From first dose up to 21 days
Secondary Stage 1: Pharmacokinetics: Area Under Curve (AUC) with immunoanalytical method AUC will be recorded from the PK serum samples collected. Up to progression of disease after injection, or end of 6 cycle( each cycle is 28 days), whichever came first
Secondary Stage 2: Pharmacokinetics: Area Under Curve (AUC) with immunoanalytical method AUC will be recorded from the PK serum samples collected. Up to progression of disease after injection, or end of cycle 6 (each cycle is 21 days), whichever came first
Secondary Stage 1: Pharmacokinetics: clearance rate (CL) with immunoanalytical method AUC will be recorded from the PK serum samples collected. Up to progression of disease after injection, or 6 cycle( dose increase), 8 cycle (dose extension), whichever came first
Secondary Stage 2: Pharmacokinetics: clearance rate (CL) with immunoanalytical method AUC will be recorded from the PK serum samples collected. Up to progression of disease after injection, or end of cycle 6 (each cycle is 21 days), whichever came first
Secondary Stage 1: Pharmacokinetics: minimum concentration (Cmin) with immunoanalytical method AUC will be recorded from the PK serum samples collected. Up to progression of disease after injection, or end of cycle 6(dose increase stage), or cycle 8 (dose expansion stage), each cycle is 28 days, whichever came first
Secondary Stage 2: Pharmacokinetics: minimum concentration (Cmin) with immunoanalytical method AUC will be recorded from the PK serum samples collected. Up to progression of disease after injection, or end of cycle 6 (each cycle is 21 days), whichever came first
Secondary Stage 1: Pharmacokinetics: maximum concentration (Cmax) with immunoanalytical method AUC will be recorded from the PK serum samples collected. Up to progression of disease after injection, or end of cycle 6(dose increase stage), or cycle 8 (dose expansion stage), each cycle is 28 days, whichever came first
Secondary Stage 2: Pharmacokinetics: maximum concentration (Cmax) with immunoanalytical method AUC will be recorded from the PK serum samples collected. Up to progression of disease after injection, or end of cycle 6 (each cycle is 21 days), whichever came first
Secondary Stage 1: Pharmacokinetics: half-life (T1/2) with immunoanalytical method AUC will be recorded from the PK serum samples collected. Up to progression of disease after injection, or end of cycle 6(dose increase stage), or cycle 8 (dose expansion stage), each cycle is 28 days, whichever came first
Secondary Stage 2: Pharmacokinetics: half-life (T1/2) with immunoanalytical method AUC will be recorded from the PK serum samples collected. Up to progression of disease after injection, or end of cycle 6 (each cycle is 21 days), whichever came first
Secondary Stage 1: volume of distribution (Vd) with immunoanalytical method AUC will be recorded from the PK serum samples collected. Up to progression of disease after injection, or end of cycle 6(dose increase stage), or cycle 8 (dose expansion stage), each cycle is 28 days, whichever came first
Secondary Stage 2: volume of distribution (Vd) with immunoanalytical method AUC will be recorded from the PK serum samples collected. Up to progression of disease after injection, or end of cycle 6 (each cycle is 21 days), whichever came first
Secondary Immunogenicity Incidence of anti-drug antibodies Up to 8 months (end of treatment)
Secondary Efficacy: objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) These measure are defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1. Up to progression of disease after injection, or 6 months( stage 1), 12 months (stage 2) whichever came first
Secondary Efficacy: disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) These measure are defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1. Up to progression of disease after injection, or 6 months( stage 1), 12 months (stage 2) whichever came first
Secondary Efficacy: duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) These measure are defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1. Up to progression of disease after injection, or 6 months( stage 1), 12 months (stage 2) whichever came first
Secondary Efficacy: progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) These measure are defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1. Up to progression of disease after injection, or 6 months( stage 1), 12 months (stage 2) whichever came first
Secondary Efficacy: overall survival (OS) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) These measure are defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1. Up to progression of disease after injection, or 6 months( stage 1), 12 months (stage 2) whichever came first
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2